Safety Overview

The GLP-1 RA Safety Landscape

Class profile · Incidence hierarchy · Red flags

GLP-1 receptor agonists have one of the most extensively characterised safety profiles in modern pharmacology — with over 150,000 patient-years of randomised clinical trial exposure across the SUSTAIN, SURPASS, STEP, SURMOUNT, LEADER, SELECT, FLOW, and PIONEER programmes, supplemented by years of post-marketing surveillance data in millions of real-world patients. The class is broadly well-tolerated, with a safety profile dominated by gastrointestinal effects — most of which are predictable, dose-dependent, and self-limiting. Serious adverse events are rare but include pancreatitis, thyroid malignancy (animal data), retinopathy worsening in T2DM, and aspiration under anaesthesia.

20–30%
Nausea incidence at initiation (most common AE)
4–7%
Discontinuation due to GI side effects
<0.3%
Acute pancreatitis — rare but serious
+2–4 bpm
Mean resting heart rate increase (class effect)
Very common · >10%
Nausea
20–44%
Titration-dependent · Weeks 1–8 · Usually self-limiting
Very common · >10%
Diarrhoea
13–30%
Higher with tirzepatide · Usually transient
Common · 5–15%
Constipation
5–15%
More persistent than diarrhoea · Fibre + fluids
Common · 5–10%
Dyspepsia / Reflux
5–13%
Gastric emptying delay · Heartburn · Bloating
Common · Class effect
Heart rate increase
+2–4 bpm
Sustained · Monitor in arrhythmia · Mechanism known
Common · 1–3%
Cholelithiasis
1.5–3%
Rapid weight loss mechanism · Screen at risk patients
Uncommon · <0.5%
Acute Pancreatitis
<0.3%
Serious · Absolute CI after confirmed episode
Uncommon · T2DM
Retinopathy worsening
HR 1.76
SUSTAIN-6 signal · Screen before sema in T2DM
Emerging · Under review
Neuropsychiatric
Signal
Suicidality signal · FDA review resolved Jan 2026: no causal link established
💡
The Most Important Safety Principle for GLP-1 RAs
The vast majority of GLP-1 RA adverse effects are dose-dependent, titration-related, and self-limiting. The single most effective intervention for managing side effects is slower dose titration — not discontinuation. Patients who discontinue GLP-1 RAs due to GI side effects in weeks 1–4 would often have tolerated the drug if titration had been slowed. Pre-treatment counselling on expected side effect timing, severity, and duration is the most evidence-based intervention for improving tolerability and reducing early discontinuation.
Agent Comparison

Side Effect Profile Differences by Agent

Not all GLP-1 RAs have the same safety profile — clinically important differences

Side effect Sema SC (1–2 mg) Sema 2.4 mg Tirzepatide 15 mg Dulaglutide Liraglutide Exenatide XR
Nausea
~20%
~44%
~31%
~15%
~26%
~11%
Vomiting ~8% ~24% ~19% ~6% ~15% ~4%
Diarrhoea ~9% ~30% ~26% ~13% ~17% ~7%
Constipation ~5% ~24% ~15% ~6% ~11% ~3%
GI discontinuation ~5% ~7% ~4.5% ~5% ~9% ~3%
Heart rate ↑ +2–3 bpm +4 bpm +2–3 bpm +2 bpm +3 bpm +2 bpm
Cholelithiasis ~1.5% ~2.6% ~1.2% ~1.3% ~3.0% ~1.0%
Retinopathy signal SUSTAIN-6 HR 1.76 Not seen (SELECT) Limited data Not seen (REWIND) Not seen (LEADER) Not seen (EXSCEL)
Injection site reactions ~2% ~2% ~3.5% ~2% ~3% ~13% (nodules)
Hair loss ~3% ~3–5% ~5% ~2% ~2% ~1%
📊
Key Pattern: Dose Matters Most
The dominant predictor of GI side effect burden is dose magnitude, not the specific agent. Semaglutide 2.4 mg (Wegovy) causes substantially more nausea and vomiting than semaglutide 1 mg (Ozempic) — despite being the same molecule. Tirzepatide at 15 mg produces more diarrhoea than at 5 mg. This dose-dependence means staying at the lowest effective dose is the most important tolerability strategy — and that escalating patients to maximum dose when lower doses achieve clinical targets is poor practice.
GI Side Effects · Most Common

Nausea & Vomiting

🤢
Nausea & Vomiting
Very Common · >10% Self-limiting · Weeks 1–8 Most common reason for discontinuation
20–44%
Nausea incidence (dose-dependent)
Mechanism
GLP-1R activation in the area postrema (vomiting centre, outside the blood-brain barrier) and nucleus tractus solitarius (NTS) is the primary mechanism for GLP-1 RA-induced nausea. Simultaneously, gastric emptying delay causes gastric distension and early satiety that reinforces the nausea signal. At higher doses (semaglutide 2.4 mg, tirzepatide 15 mg), the hypothalamic appetite-suppressing signal itself may contribute via NTS activation, explaining why nausea is more prominent at initiation when dose escalation is rapid. Tachyphylaxis of the area postrema response explains why nausea improves with continued exposure — the receptor downregulates, attenuating the emetogenic signal while preserving glucose-lowering effects.
Incidence by Agent & Dose
Agent / Dose Nausea Vomiting Severe (>grade 2) Leading to discontinuation
Semaglutide SC 0.5 mg 15% 5% 2% 2%
Semaglutide SC 1 mg 20% 8% 3% 3%
Semaglutide SC 2.4 mg (Wegovy) 44% 24% 8% 5%
Tirzepatide 5 mg 17% 7% 2% 2%
Tirzepatide 10 mg 22% 13% 3% 3%
Tirzepatide 15 mg 31% 19% 5% 4.5%
Dulaglutide 1.5 mg 15% 6% 2% 2.5%
Liraglutide 1.8 mg 26% 15% 4% 7%
Oral semaglutide 14 mg 20% 9% 3% 11%
Management Protocol
📋
Before initiating: Counsel all patients that nausea is expected in weeks 1–8, peaks at dose escalation steps, and improves with time. Set realistic expectations — "this is not a signal to stop; it is expected and temporary." Provide written information on dietary modifications before first injection.
1
Dietary modifications (first-line): Eat small, frequent meals (5–6 per day rather than 3 large). Avoid fatty, spicy, or very sweet foods during dose-escalation period. Eat slowly and stop at first sense of fullness — the drug exaggerates satiety signals. Avoid lying down for 1–2 hours after eating. Cold or room-temperature foods are often better tolerated than hot meals.
2
Dose titration adjustment: If nausea is ≥moderate (affecting quality of life or food intake): do not escalate to the next dose step. Remain at the current dose for an additional 4 weeks (total 8 weeks at current dose) before retrying escalation. There is no clinical mandate to reach maximum dose — some patients do well long-term at sub-maximal doses.
3
Persistent or troublesome nausea: reassess dose escalation, hydration and possible alternative causes. A clinician may consider short-term symptom treatment after checking contraindications and interactions; do not use a universal antiemetic regimen.
4
Injection timing adjustment: For weekly SC injections — experiment with timing (morning vs evening). Some patients find evening injections reduce daytime nausea. For oral semaglutide — the fasting requirement amplifies nausea in some patients; ensure tablet is swallowed whole (not chewed) and the 30-minute fast is strictly observed.
⚠
Vomiting persisting >48 hours: Do not administer next dose while actively vomiting. Ensure adequate hydration. Check renal function if on ACEi/ARBi/SGLT2i/NSAIDs (AKI risk from volume depletion). If unable to maintain oral fluids after 48 hours — seek medical review; IV fluids may be required. Withhold SGLT2i and NSAIDs during significant GI illness.
✗
Stop drug if: Persistent severe vomiting (>3 days) despite dose hold and antiemetics; clinical dehydration with hypotension; inability to tolerate oral fluids; or acute pancreatitis suspected (upper abdominal pain radiating to back — check serum lipase urgently). Do not resume until cause clarified.
💡
When Nausea is Actually a Good Sign
Counter-intuitively, patients who experience moderate early nausea with GLP-1 RAs often achieve greater long-term weight loss — the nausea reflects robust GLP-1R activation in the area postrema and NTS, the same signalling that drives appetite suppression. The goal is to manage nausea to a tolerable level, not eliminate it entirely. Patients with no nausea whatsoever may occasionally be non-responders or may have been prescribed counterfeit product (a real pharmacovigilance concern with online/unlicensed purchasing).
GI Side Effects

Diarrhoea

🚽
Diarrhoea
Very Common · 10–30% Higher with tirzepatide & high-dose sema
13–30%
Diarrhoea incidence (by agent)
Mechanism
GLP-1R activation in intestinal enteroendocrine cells and myenteric plexus neurons increases intestinal motility — the opposite effect to gastric emptying delay. In the stomach, GLP-1 RAs slow emptying; in the small and large intestine, they accelerate transit. This discordant effect (slow proximal, fast distal) explains why some patients experience concurrent constipation and diarrhoea — alternating bowel habit is common early in treatment. Tirzepatide's higher diarrhoea incidence (26% at 15 mg) may relate to its GIPR agonism altering intestinal secretory function in addition to GLP-1R effects on motility.
Management
1
Dietary adjustment: Reduce high-fibre foods, lactose, and high-fat foods temporarily during dose escalation. BRAT diet (bananas, rice, applesauce, toast) acutely. Avoid sorbitol-containing foods and drinks. Reintroduce normal diet gradually once bowel habit stabilises.
2
Loperamide 2–4 mg PRN: Safe and effective for GLP-1 RA-associated diarrhoea. Can be used prophylactically on dose escalation days if diarrhoea is predictable. Not suitable if any concern about infective cause or inflammatory bowel disease.
3
Hydration: Oral rehydration salts (ORS) if >4 loose stools per day. Monitor for hyponatraemia in elderly patients. Withhold metformin if significant diarrhoea (lactic acidosis risk from dehydration + metformin). Review concurrent SGLT2i dose (dehydration risk compounds).
⚠
Investigate if: Blood in stool; fever; severe abdominal cramps; diarrhoea lasting >7 days without improvement; new diarrhoea after weeks of stable therapy (consider new cause — C. difficile, IBD, new onset coeliac). Rule out infective cause before attributing to GLP-1 RA.
GI Side Effects

Constipation

🔒
Constipation
Common · 5–24% More persistent than nausea
5–24%
Highest at obesity doses
Mechanism & Clinical Pattern
Gastric emptying delay reduces intestinal motility globally, though the magnitude varies by intestinal segment. In the large intestine, reduced colonic transit time leads to increased water absorption from stool, resulting in constipation. Unlike nausea, constipation may not improve with time and can persist throughout treatment — particularly at higher doses. The combination of reduced food intake (smaller appetite) reducing bowel habit frequency, decreased physical activity (energy conservation during rapid weight loss), and direct GLP-1R colonic effects all contribute. Constipation at high-dose sema 2.4 mg (24%) is particularly common and clinically significant, sometimes requiring pharmacological laxative intervention indefinitely while on therapy.
Management
1
Increase fluid and fibre intake: Target 2L water/day; 25–30g dietary fibre daily. Psyllium husk (ispaghula) 3.5–7g OD in water — first-line bulk-forming agent, safe and effective long-term.
2
Osmotic laxatives if dietary measures insufficient: Macrogol (polyethylene glycol) 17g OD-BD — safe, well-tolerated, non-habit forming. Lactulose 15–30ml BD is an alternative. Avoid stimulant laxatives (senna, bisacodyl) as first-line — reserve for acute constipation relief.
3
Physical activity: Recommend 30 minutes daily walking — exercise is independently associated with improved bowel transit and should be part of obesity management anyway.
⚠
Monitor for faecal impaction in elderly, immobile, or opioid-using patients. Alert re: ileus/obstruction: If constipation is accompanied by abdominal distension, absent bowel sounds, or severe pain — suspect ileus (see bowel obstruction section). This is a rare but serious complication, particularly relevant in the context of FDA safety communications in 2023–2024.
GI Side Effects

Dyspepsia, Reflux & Bloating

🔥
Dyspepsia · Heartburn · Abdominal Bloating
Common · 5–13% Gastric emptying delay mechanism
5–13%
Dyspepsia incidence
Gastric emptying delay causes gastric contents to remain in the stomach longer, increasing intragastric pressure and promoting reflux of acidic content into the oesophagus. Patients describe a sensation of prolonged fullness after small meals, upper abdominal bloating, belching, and heartburn — distinct from the nausea of direct emetic centre activation. Abdominal bloating is particularly prominent with tirzepatide and may persist beyond the initial titration phase. Pre-existing GORD is not a contraindication but symptoms will likely worsen during dose escalation.
Management
1
PPI therapy: Omeprazole 20 mg OD or lansoprazole 15–30 mg OD — first-line for symptomatic dyspepsia/heartburn. Review PPI interaction with oral semaglutide (PPIs reduce gastric acidity, potentially improving Rybelsus absorption; take oral sema ≥30 minutes before PPI).
2
Dietary: Small meals; avoid lying down after eating (2-hour rule); elevate head of bed; avoid alcohol and caffeine; reduce meal size further if bloating is dominant symptom.
3
Simethicone (activated dimethicone) for bloating and flatulence — safe, effective, non-systemic. Peppermint oil capsules (IBS-standard preparation) may reduce colonic spasm and bloating.
Serious gastrointestinal warning

Acute Pancreatitis

Recognise severe, persistent abdominal pain
MHRA warning strengthened · 29 January 2026

Pancreatitis is a recognised adverse effect. Updated UK warnings include rare necrotising and fatal reports. It is a warning/precaution, not an FDA boxed warning for pancreatitis.

1
If pancreatitis is suspected, stop the medicine and arrange urgent medical assessment. Severe persistent abdominal pain, sometimes radiating to the back, requires assessment rather than reassurance as routine titration nausea.
2
After confirmed pancreatitis, the suspected medicine should not be restarted. A previous episode requires individual caution and the relevant product information.

Diagnosis and treatment follow acute-pancreatitis guidance. An isolated enzyme rise does not establish the diagnosis; this page does not supply a fluid, imaging or feeding protocol.

Source: MHRA Drug Safety Update, 29 January 2026.

Serious GI · Post-Marketing Signal 2023

Bowel Obstruction & Ileus

🚨
Intestinal Obstruction / Paralytic Ileus
FDA Safety Communication · September 2023 Rare · Post-marketing signal
Rare
Post-marketing · FAERS reports
Background & FDA Action
In September 2023, the FDA issued a safety communication adding intestinal obstruction (including ileus) to the GLP-1 RA class label as a potential adverse effect, following analysis of FAERS (FDA Adverse Event Reporting System) spontaneous reports. The cases were predominantly in patients on semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda), though the signal extended across the class. A 2023 observational study (JAMA Internal Medicine, Sodhi et al., n=4,855) found GLP-1 RA users had a significantly higher risk of ileus (OR 3.95) and bowel obstruction (OR 2.53) compared with bupropion-naltrexone users — a finding that generated significant clinical and regulatory attention. Importantly, this was an observational study with significant confounders; RCT data do not demonstrate a statistically significant signal in primary analyses.
Clinical Recognition & Management
🚨
Red flag symptoms — urgent ED referral: Abdominal distension; absent or tinkling bowel sounds; absolute constipation (no passage of stool or flatus); progressive abdominal pain; vomiting of faeculent material; clinical dehydration with tachycardia/hypotension. These features are not consistent with routine GLP-1 RA GI side effects and require urgent surgical assessment. AXR and CT abdomen are first-line investigations.
⛔
Stop GLP-1 RA if intestinal obstruction or ileus confirmed. Do not re-challenge until underlying cause (adhesions, volvulus, or drug-related motility disorder) has been clarified. Surgical or gastroenterology review required before any re-prescribing decision.
⚠
High-risk patients to monitor: Prior abdominal surgery (adhesion risk); prior bowel obstruction; severe constipation on therapy that does not respond to laxatives; opioid co-prescribing (compounds GI motility reduction). Counsel all patients: if constipation worsens with bloating and absent flatus — do not take the next GLP-1 RA dose and seek medical review.
Serious GI

Gastroparesis — Worsening & Unmasking

🔄
Gastroparesis — Worsening or New Diagnosis
Severe gastroparesis: specialist caution Unmasking of subclinical disease
GLP-1 RAs delay gastric emptying — the therapeutic mechanism that contributes to postprandial glucose control. In patients with pre-existing subclinical or mild diabetic gastroparesis (estimated to affect 30–50% of longstanding T2DM), this additional emptying delay may unmask or dramatically worsen gastroparesis symptoms: prolonged early satiety, nausea hours after eating (not immediately as with typical GLP-1 RA nausea), vomiting of undigested food, significant weight loss beyond expected, bloating, bezoar formation. Confirmed or severe gastroparesis requires product-specific review and specialist risk assessment; it is not a universal UK class contraindication. Current tirzepatide SmPC wording advises caution in severe gastrointestinal disease, including severe gastroparesis. In practice, pre-existing gastroparesis is frequently undiagnosed; clinicians should ask about symptoms before prescribing and refer for scintigraphy if suspected.
1
If gastroparesis is confirmed on therapy: Withhold treatment and review the product-specific SmPC and individual risk with diabetes/gastroenterology specialists; permanent discontinuation is a clinical decision, not a universal class rule. Refer for gastroparesis management (dietary modification, prokinetics — domperidone, metoclopramide; endoscopic or surgical options in refractory cases). Address underlying diabetic autonomic neuropathy.
⚠
Pre-prescribing: Specifically ask about symptoms of early satiety, postprandial bloating lasting hours, vomiting of undigested food, and unexplained weight loss before GLP-1 RA initiation. If present — arrange gastric emptying scintigraphy before prescribing. Do not attribute these symptoms post-hoc to "GLP-1 RA side effects" without investigation.
⚠
Anaesthetic risk: Gastroparesis significantly amplifies the aspiration risk under general anaesthesia. If a patient on a GLP-1 RA is found to have gastroparesis and requires surgery — this is a critical anaesthetic risk factor. Inform the anaesthetic team immediately. See Anaesthesia section for full protocol.
Endocrine · jurisdiction-specific labelling

Thyroid C-cell tumour warning

Semaglutide produced C-cell tumours in rodents; human relevance is uncertain. US Ozempic labelling includes a boxed warning and contraindications for personal/family medullary thyroid carcinoma or MEN2. Those US restrictions must not be presented as universal UK contraindications.

Do not promise that human risk is absent. Assess neck masses, persistent hoarseness, swallowing difficulties or known nodules through the appropriate clinical pathway. Routine calcitonin or ultrasound screening solely because a patient takes Ozempic has uncertain value; this site does not recommend a fixed surveillance schedule.

Sources: US Ozempic prescribing information, sections 4 and 5.1; UK Ozempic SmPC.

Ophthalmology · retinopathy and NAION

Visual symptoms and diabetic retinopathy

Rapid improvement in glycaemia can temporarily worsen diabetic retinopathy. Review existing retinopathy and screening arrangements, and coordinate treatment with the retinal team when appropriate. A universal extended titration or fixed rescreening interval is not established by this observation.

Sudden loss of vision, including partial loss, needs urgent ophthalmological assessment. Semaglutide product information now includes non-arteritic anterior ischaemic optic neuropathy (NAION); stop semaglutide if NAION is confirmed. NAION is distinct from diabetic retinopathy.

Source: current UK Wegovy SmPC, sections 4.4 and 4.8.